Seroprevalence of Hepatitis C virus (HCV) infection and role of serological and molecular assay in HCV detection and management: A step towards achieving the aim of National Viral Hepatitis Control Program (NVHCP)
DOI:
https://doi.org/10.37506/4zbz6f44Keywords:
Serology, Molecular, DAA, NVHCPAbstract
Purpose:
Hepatitis C virus (HCV) is a small, enveloped, single stranded RNA virus of Flaviviridae
family. HCV causes both acute and chronic infection. Diagnosis of HCV can be done by indirect serological tests that detect antibodies against HCV (anti-HCV) and direct test that
detects and quantifies components of viral RNA particles. As per CDC recommendation;
HCV testing should be initiated with anti-HCV test, those anti-HCV positive/reactive should
have follow-up testing with Nucleic Acid Test. If the HCV RNA is detected, patient should be directed for the treatment with highly effective direct acting antiviral (DAA). This study aims to determine the seroprevalence of HCV infection, to estimate presumptive HCV infection by using serological assay by anti-HCV ELISA, to estimate the current HCV infection by detecting HCV-RNA using RT-PCR molecular assay and, to highlight the role of HCV RNA for initiation of treatment.
Methods:
This study is retrospective observational analysis of 36500 samples obtained for anti-HCV
ELISA test from Jan to Dec 2022. The ELISA kit used was a 3rd generation sandwich assay.
All ELISA positive samples were tested for HCV RNA, by automated qRT-PCR method.
Results:
Out of 36500 samples, 361 tested positive by anti-HCV ELISA with 0.9% seroprevalence.
Out of 361, only 336 were tested for HCV RNA. Of 336, 240 samples were negative as target not detected, and 96 samples showed values as viral copies in IU/mL. Most common age group affected was 18-40 years, for both serology and molecular test.
Conclusion:
In current study, only 96 samples showed viral copies indicating current HCV infection and need to start treatment. Hepatitis C is curable; with the availability of highly effective DAA both in a brand and generic form can cure > 95% of infected people, so the possibility of achieving the target of elimination HCV by 2030 can be predicted.
References
https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Khudur Al-Nassary MS, Mahdi BM. Study of Hepatitis C Virus Detection Assays. Ann Med Surg (Lond). 2018 Oct 6;36:47-50. doi: 10.1016/j.amsu.2018.10.002. PMID:30377525; PMCID: PMC6202795.
Barrera JM, Franscis B, Ercilla G, Nelles M, Archod D, Darner J, et al. Improved detection of Anti-HCV in Post transfusion Hepatitis by third generation ELISA. VoxSang 1995;68:15-8
Forman MS, Valsamakis A. Hepatitis C virus. In: Versalovic J, Carrol KC, Funke G, Jorgensen JH, Landry ML, Warrock DW, editors. Murray’s Manual of Clinical Microbiology. 10th ed. Washington: American Society of Microbiology Press; 2011. p.1437-55.
Rajkumar MS, Smeeta H, Shanta D, Provash CS, Khumukcham LS. Comparative Evaluation of Three Diagnostic Tools for the Detection of Hepatitis C Virus among High-risk Individuals in a Tertiary Care Centre of Northeast India. J of Clin and Diagn Res.2022 Jul, Vol-16(7): DC13-DC17
Daniel HD, Grant PR, Garson JA, Tedder RS, Chandy GM, Abraham P. Quantitation of hepatitis C virus using an in-house real-time reverse transcriptase polymerase chain reactionin plasma samples. Diagn Microbiol Infect Dis. 2008;61(4):415Doi:10.1016/j.diagmicrobio.2008.04.001.
Berry N, Chakravarti A, Das U, Kar P, Das BC and Mathur MD. HCV seroreactivity and detection of HCV RNA in cirrhotics. Diag Microbiol Infec Dis. 1999; 35(3): 209-13.
https://www.cdc.gov/hepatitis/hcv/pdfs/hcv_flow.pdf
American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). Recommendations for testing, management, and treating hepatitis C: HCV testing and linkage to care. Available at: https://www.hcvguidelines.org
https://nvhcp.mohfw.gov.in/about_us
Jindal N, Soin D, Grover P, Bansal R, Malhotra R, Singh S, Singh C. Hepatitis C Virus(HCV) Infection among Seronegative Patients undergoing Haemodialysis in a RemotelyLocated Tertiary Care Hospital of Northern India: Value of HCV-RNA and Genotypes. JClin Diagn Res. 2015 Dec;9(12):DC10-2. doi: 10.7860/JCDR/2015/15310.6952. Epub2015
Kumar M, Verma RK, Singh M, Nirjhar S, Chaudhary R. Seroprevalence of HCVinfection at a tertiary care hospital, western Uttar Pradesh, India. Int J Res Rev.2019;6(4):01-09.
Goel A, Seguy N, Aggarwal R. Burden of hepatitis C virus infection in India: Asystematic review and meta-analysis. J Gastroenterol Hepatol. 2019 Feb ;34(2):321-329.doi: 10.1111/jgh.14466. Epub 2018 Sep 26. PMID: 30176181.
Goel A, Rewari BB, Sharma M, Konath NM, Aggarwal R. Seroprevalence and burden ofhepatitis C virus infection in WHO South-East Asia Region: A systematic review. JGastroenterol Hepatol. 2022 Jun;37(6):964-972. doi: 10.1111/jgh.15827. Epub 2022 Mar PMID: 35263807.
Hepatitis-C-in-the-WHO-European-Region-factsheet-July-2022World HealthOrganization (WHO). Hepatitis C Fact sheet. Geneva: WHO. [Accessed 24 Oct 2016].Available from: http:// www.who.int/mediacentre/factsheets/fs164/en
Sachdeva S, Mehta B. Population-based hepatitis C survey in a rural block. N Am J MedSci. 2012 Nov;4(11):591-2. doi: 10.4103/1947-2714.103325. PMID: 23181234; PMCID:PMC3503381.
Garvey P, O'Grady B, Franzoni G, Bolger M, Irwin Crosby K, Connell J, Burke D, DeGascun C, Thornton L. Hepatitis C virus seroprevalence and prevalence of chronicinfection in the adult population in Ireland: a study of residual sera, April 2014 toFebruary 2016. Euro Surveill.2017Jul27;22(30):30579.doi:10.2807/1560-7917.ES.2017.22.30.30579.PMID: 28797323; PMCID: PMC5553053.
https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/data-and-trends/index.html
Chowdhury A, Santra A, Chaudhuri S, Dhali GK, Chaudhuri S, Maity SG, Naik TN,Bhattacharya SK, Mazumder DN. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology. 2003 Apr;37(4):802-9. doi:10.1053/jhep.2003.50157. PMID: 12668973
Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. Prevalence of hepatitis C virus infection in the United States. 1988 through1994. N Engl J Med 1999;341:556-562
https://nvhcp.mohfw.gov.in/common_libs/national-laboratory-guidelines.pdf pg 22
Laboratory Tests and Hepatitis C - Viral Hepatitis and Liver Disease (va.gov)
S Kaya, Buket CA, Emel SC, Ali KA, M Demirci. Comparison of polimerase chain reaction and serological methods in the diagnosis of hepatitis C virus infection.S.D.Ü. Tıp Fak. Derg. 2007;14(1):10-14.
Hepatitis-C-in-the-WHO-European-Region-factsheet-July-2022
Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015 Jan 17;15:19.
Andrieux-Meyer I, Cohn J, de Araújo ES, Hamid SS. Disparity in market prices forhepatitis C virus direct-acting drugs. Lancet Glob Health. 2015 Nov;3(11):e676-7. doi:10.1016/S2214-109X(15)00156-4. PMID: 26475012.
Tang L, Kamat M, Shukla A, Vora M, Kalal C, Kottilil S, Shah S. Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. Interdiscip Perspect Infect Dis. 2018 Oct 1;2018:9124604.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Vaishali Solanke-Surase, Shashir Wanjare, RanjanaN.Thate, ChayaA.Kumar, Gita Nataraj

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
https://creativecommons.org/licenses/by-nc/2.0/deed.en